Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.59 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.47 |
| ▸ | KMO | O15229 | 1/20 | 0.46 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.45 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.45 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.45 |
| ▸ | CKS1B | P61024 | 2/20 | 0.44 |
| ▸ | SKP1 | P63208 | 2/20 | 0.44 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 1/20 | 0.43 |
| ▸ | TBK1 | Q9UHD2 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3268033 | 0.88 | SMARCA2 (0.53) | FAAHMAP4K4GPR119SMARCA2SMARCA4 | |
| SCHEMBL3270107 | 0.86 | MAP4K4 (0.50) | MAP4K4GPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL3268523 | 0.84 | SMARCA2 (0.48) | FAAHMAP4K4GPR119SMARCA2SMARCA4 | |
| SCHEMBL3269829 | 0.83 | CKS1B (0.52) | MAP4K4GPR119KMOSMARCA2SMARCA4 | |
| SCHEMBL3267623 | 0.83 | FAAH (0.60) | FAAHGPR119CKS1BSKP1SKP2 | |
| SCHEMBL3268450 | 0.83 | FAAH (0.60) | FAAHMAP4K4GPR119SMARCA2SMARCA4 | |
| SCHEMBL3269757 | 0.83 | FAAH (0.60) | FAAHGPR119SMARCA2SMARCA4PBRM1 | |
| SCHEMBL3268897 | 0.82 | CKS1B (0.48) | FAAHMAP4K4GPR119SMARCA2SMARCA4 | |
| SCHEMBL3269713 | 0.80 | FAAH (0.61) | FAAHGPR119KMOSMARCA2SMARCA4 | |
| SCHEMBL3272042 | 0.80 | FAAH (0.61) | FAAHMAP4K4GPR119CKS1BSKP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234389-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2199282-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-06-23 | — | — | EP | disclosed |
| US-20090163508-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234389-A1 | AMIDE COMPOUND | FAAH, FAAH2, NAAA | FAAH 1/4885MAP4K4 2554/4885GPR119 996/4885 |
| US-20090163508-A1 | AMIDE COMPOUND | FAAH, FAAH2, NAAA | FAAH 1/4885MAP4K4 2554/4885GPR119 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.